AMINOSYN SOLUTION

Երկիր: Կանադա

Լեզու: անգլերեն

Աղբյուրը: Health Canada

Ակտիվ բաղադրիչ:

L-ALANINE; L-ARGININE; GLYCINE; HISTIDINE; L-LEUCINE; L-ISOLEUCINE; L-LYSINE (L-LYSINE ACETATE); METHIONINE; L-PHENYLALANINE; L-PROLINE; SERINE; L-THREONINE; TRYPTOPHAN; L-TYROSINE; L-VALINE

Հասանելի է:

ICU MEDICAL CANADA INC

ATC կոդը:

B05BA01

INN (Միջազգային անվանումը):

AMINO ACIDS

Դոզան:

1280MG; 980MG; 1280MG; 300MG; 940MG; 720MG; 720MG; 400MG; 440MG; 860MG; 420MG; 520MG; 160MG; 44MG; 800MG

Դեղագործական ձեւ:

SOLUTION

Կազմը:

L-ALANINE 1280MG; L-ARGININE 980MG; GLYCINE 1280MG; HISTIDINE 300MG; L-LEUCINE 940MG; L-ISOLEUCINE 720MG; L-LYSINE (L-LYSINE ACETATE) 720MG; METHIONINE 400MG; L-PHENYLALANINE 440MG; L-PROLINE 860MG; SERINE 420MG; L-THREONINE 520MG; TRYPTOPHAN 160MG; L-TYROSINE 44MG; L-VALINE 800MG

Կառավարման երթուղին:

INTRAVENOUS

Միավորները փաթեթում:

500ML/1000ML

Ռեկվիզորի տեսակը:

Ethical

Թերապեւտիկ տարածք:

CALORIC AGENTS

Ապրանքի ամփոփագիր:

Active ingredient group (AIG) number: 1550865003; AHFS:

Լիազորման կարգավիճակը:

CANCELLED POST MARKET

Հաստատման ամսաթիվը:

2019-01-24

Ապրանքի հատկությունները

PRESCRIBING INFORMATION
AMINOSYN
TM
(amino acids for injection 10%)
SULFITE-FREE
NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION
ICU Medical Canada Inc.
Date of Revision: December 21, 2017
2600, Alfred-Nobel boul., suite 100
St-Laurent, Quebec
H4S 0A9
Control No. 210260
_PRESCRIBING INFORMATION; Aminosyn_
_TM_
_ _
_ _
_Page 2 of 13 _
NAME OF DRUG:
AMINOSYN
TM
(amino acids for injection 10%)
Sulfite-Free
THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION
Nutritive Supplement for Intravenous Infusion
ACTION
1.
PROTEIN SPARING (PERIPHERAL USE)
:
It has been shown that it may be preferable for short periods of time,
3 to 5 days, to mobilize fat (as
in total starvation) for meeting energy requirements to spare protein.
Under conditions of total fasting, lipid mobilization provides energy
substrate in the form of free fatty
acids and ketone bodies. Lipolysis occurs because insulin levels are
low. If high concentrations of
carbohydrates are administered, insulin levels will rise and inhibit
lipid mobilization. With brief
periods of fasting (less than 24 hours), energy requirements are
usually met by glycogenolysis of the
glycogen stored in the liver. However, after glycogen is depleted,
lipolysis of body fat becomes the
fat source of energy.
Thus, when amino acids (without dextrose) are infused into a
peripheral vein, lipolysis and
ketogenesis occur freely and caloric requirements are met without
proteolysis. This spares protein
and the body's muscle mass, while providing a substrate for essential
protein synthesis.
Amino acid peripheral intravenous infusions result in: (1)
availability of free fatty acids and ketone
bodies as sources of energy, and (2) the concomitant utilization of
administered amino acids for
protein synthesis.
2.
ADJUNCTIVE FOR TOTAL PARENTERAL NUTRITION (TPN)
:
Central vein infusion should be considered when amino acid solutions
are to be admixed with
sufficient dextrose to meet fully caloric energy requirements for
protein synthesis in patients
requiring prolonged total parenteral nutrition. Because of t